These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18230873)

  • 1. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
    Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH
    Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
    Hengstman GJ; van den Hoogen FH; van Engelen BG
    Eur Neurol; 2004; 52(1):61-3. PubMed ID: 15240986
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab for refractory polymyositis: an open-label prospective study.
    Mok CC; Ho LY; To CH
    J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
    Efthimiou P; Schwartzman S; Kagen LJ
    Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
    Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
    J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
    Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment in patients with refractory inflammatory myopathies.
    Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
    Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G; Ebert A; Fitter S; Minden K; Foeldvari I; Kümmerle-Deschner J; Thon A; Girschick HJ; Weller F; Huppertz HI
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE; Geborek P; Saxne T
    Rheumatology (Oxford); 2009 Mar; 48(3):243-5. PubMed ID: 19106164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab as therapy for refractory polymyositis and dermatomyositis.
    Noss EH; Hausner-Sypek DL; Weinblatt ME
    J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic advances in myositis.
    Aggarwal R; Oddis CV
    Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
    Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine.
    Gelinck LB; van der Bijl AE; Visser LG; Huizinga TW; van Hogezand RA; Rijkers GT; Kroon FP
    Vaccine; 2008 Jun; 26(27-28):3528-33. PubMed ID: 18502006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.